Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NIH

Moderna co-founder Robert Langer: ‘I wanted to use my chemical engineering to help people’

The celebrated US scientist and inventor on not being in it for the money, why diversity improves problem-solving, and his dedication to exercising

The Guardian - UK

NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185

SAB Biotherapeutics Inc (NASDAQ:SABS) said that due to low hospitalization and death rates in the trial, the National Institutes of Health's (NIH) ACTIV-2 Program is discontinuing enrollment in its Phase 3 COVID-19 trial. SAB-185 was being assessed as part of Phase 3 ACTIV-2 master protocol evaluating treatments for COVID-19 in patients with…

Benzinga

The loophole to lower drug prices

A provision known as "march-in rights" lets the government intervene if drugs are being sold at unreasonable prices

Salon

From analysis to the latest developments in health,
read the most diverse news in one place.

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

Los Angeles Times

ACHV: The Final Phase III Begins

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Benzinga

The great gaslighting: how Covid longhaulers are still fighting for recognition

People with long Covid face an uphill battle convincing skeptics their malady is real – but discrediting uncommon conditions is hardly a new phenomenon

The Guardian - US

On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial

SAB Biotherapeutics Inc (NASDAQ: SABS) has

Benzinga

Read news from The Economist, FT, and more,
with one subscription

BHU scientists bring a ray of hope in Diabetic foot ulcer treatment

Scientists from the Banaras Hindu University (BHU) have found a cure for chronic wounds, particularly diabetic foot ulcers. The research findings have been published in the National Centre for Biotechnology Information (NCBI), National Institutes of Health (NIH), US.

The Times of India

1 … 19 20 21 22

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

National Institutes of Health

Banaras Hindu University

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.